Zylox-Tonbridge Medical Technology Co., Ltd. (abbr. Zylox-Tonbridge) reported a share buyback on 26 March 2026 involving 100,000 H-shares executed on the Hong Kong Stock Exchange.

The company paid a volume-weighted average price of HK$23.84 per share (high: HK$24.52; low: HK$23.56), bringing total cash outlay for the repurchase to HK$2.38 million. All repurchased shares were retained as treasury shares.

Key capital metrics after the transaction: • Issued shares outstanding (excluding treasury shares) declined by 0.03 % to 329.05 million. • Treasury share balance increased to 7.30 million. • Total issued shares remained unchanged at 336.35 million.

Mandate utilisation: • The 30 May 2025 general mandate authorises Zylox-Tonbridge to buy back up to 31.96 million shares. • Cumulative repurchases under this mandate now total 4.49 million shares, equal to 1.37 % of the issued share base when the mandate was granted.

Pursuant to Hong Kong listing rules, Zylox-Tonbridge is restricted from issuing, selling, or transferring treasury shares until 25 April 2026. The board confirmed that the repurchase was conducted in compliance with all applicable regulations and that requisite funds have been fully settled.